461030.KQ
IMBdx
KOE · Healthcare · Biotechnology · KR
KRW 2,960.00
+0.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.6B | 5.3B | 3.4B | 4.0B | 2.6B |
| Cost of Revenue | 4.3B | 4.3B | 2.5B | 2.6B | 2.3B |
| Gross Profit | 1.3B | 1.0B | 888.1M | 1.4B | 372.2M |
| Operating Expenses | |||||
| R&D Expense | 4.4B | 5.1B | 7.0B | 5.8B | 5.2B |
| SG&A Expense | 4.2B | 1.3B | 1.6B | 1.5B | 3.4B |
| General & Admin Expense | 2.8B | 460.5M | 224.0M | 144.9M | 190.8M |
| Selling & Marketing Expense | 286.9M | 816.4M | 1.4B | 1.4B | 1.2B |
| Other Expenses | 1.0B | 3.3B | 2.8B | 1.9B | 52.0M |
| Total Operating Expenses | 9.6B | 9.7B | 11.5B | 9.2B | 8.7B |
| Cost and Expenses | 14.2B | 14.0B | 14.0B | 11.8B | 11.3B |
| Operating Income (EBIT) | (8.6B) | (8.7B) | (10.6B) | (7.8B) | (8.7B) |
| Non-Operating | |||||
| Interest Income | 401.9M | 646.0M | 835.4M | 215.6M | 37.4M |
| Interest Expense | 26.3M | 24.9M | 17.7M | 943.8M | 1.3B |
| Net Interest Income | 375.7M | 621.1M | 817.7M | (728.2M) | (1.3B) |
| Other Non-Op Income/Expense | 1.0B | 730.4M | 1.0B | (2.6B) | (1.8B) |
| Non-Operating Income (excl Interest) | (473.2M) | — | (1.1B) | 1.7B | 425.6M |
| EBT (Pre-Tax Income) | (7.6B) | (7.9B) | (9.6B) | (10.4B) | (10.4B) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (7.6B) | (7.9B) | (9.6B) | (10.4B) | (10.4B) |
| Earnings from Cont. Ops | (7.6B) | (7.9B) | (9.6B) | (10.4B) | (10.4B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (7.6B) | (7.9B) | (9.6B) | (10.4B) | (10.4B) |
| Per Share | |||||
| Basic EPS | (₩539) | (₩566) | (₩683) | (₩1,316) | (₩1,948) |
| Diluted EPS | (₩539) | (₩566) | (₩683) | (₩1,316) | (₩1,948) |
| Revenue Per Share | ₩391 | ₩380 | ₩243 | ₩509 | ₩490 |
| Shares | |||||
| Basic Shares Outstanding | 14.3M | 14.0M | 14.0M | 7.9M | 5.4M |
| Diluted Shares Outstanding | 14.3M | 14.0M | 14.0M | 7.9M | 5.4M |
| Profitability Metrics | |||||
| EBITDA | (7.1B) | (7.2B) | (8.0B) | (7.8B) | (7.6B) |
| D&A | 1.3B | 1.4B | 1.6B | 1.6B | 1.5B |
| EBIT | (8.3B) | (8.7B) | (9.6B) | (9.5B) | (9.1B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026